HHS spurs development of smallpox therapeutic to enhance health security

The US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) will work with BioFactura, Inc., providing expertise and $9.5 million over two years to develop a monoclonal antibody treatment for smallpox. BARDA has options to support additional work, providing up to a total of $67.4 million over five years.

Content Information

Content Author: 
Content Source: 
US Department of Health and Human Services (HHS)
Content Type: